Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor
Автор: VJOncology
Загружено: 2020-05-30
Просмотров: 1350
Описание: Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: